Di Leo, Angelo <br/><br/>
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.  [electronic resource] 

 -  The Lancet. Oncology  Nov 2011 
 - 1134-42 p.  digital 
<br/><br/> Publication Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(11)70231-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anthracyclines--administration & dosage<br/>Antigens, Neoplasm--genetics<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biomarkers, Tumor--genetics<br/>Breast Neoplasms--drug therapy<br/>Chemotherapy, Adjuvant<br/>Chi-Square Distribution<br/>Clinical Trials, Phase III as Topic<br/>DNA Topoisomerases, Type II--genetics<br/>DNA-Binding Proteins--genetics<br/>Disease-Free Survival<br/>Evidence-Based Medicine<br/>Female<br/>Gene Amplification<br/>Gene Deletion<br/>Humans<br/>In Situ Hybridization, Fluorescence<br/>Kaplan-Meier Estimate<br/>Middle Aged<br/>Patient Selection<br/>Poly-ADP-Ribose Binding Proteins<br/>Precision Medicine<br/>Predictive Value of Tests<br/>Proportional Hazards Models<br/>Randomized Controlled Trials as Topic<br/>Receptor, ErbB-2--genetics<br/>Risk Assessment<br/>Risk Factors<br/>Survival Rate<br/>Time Factors<br/>Treatment Outcome